Company intelligence
DeepCyte
Single-Cell toxicology for drug development: Detect, Predict and Explain Drug Toxicity in Human Cells.
About DeepCyte
DeepCyte combines high-throughput single-cell metabolomics with AI to detect, predict and explain drug toxicity in human cells, before molecules reach patients. Drug Toxicity is a leading cause of clinical-trial failure and drug withdrawal, costing the industry billions each year. Animal models, high-throughput screening, and bulk assays often miss how real human cells respond. Regulators including the FDA & EMA are pushing toward human-relevant, mechanism-aware safety testing. DeepCyte's DeeTox AI platform uses laser-based sampling and mass spectrometry to profile the metabolism of individual human cells, generating Atlas-Scale, AI-ready datasets. Our first AI product, evaluated on 100 held-out drugs, predicted 17 detailed toxicity mechanisms at 94% accuracy. Our company is built on more than 10-years of academic research, with 3 patent applications filed, and a $1.5M round closed on January 2026. We operate from San Diego and Copenhagen. Follow us for research, product, and company updates.
Verified activity
Signals from DeepCyte
4 published signals
Presence & Recognition
DeepCyte CEO Theodore Alexandrov revealed at the EUROTOX Congress 2026 how DeepCyte’s AI leverages single-cell metabolomics to reveal complex toxicity mechanisms and downstream Adverse Outcome Pathway (AOP) cascades.
Reported by DeepCyte
Presence & Recognition
DeepCyte CSO Shawn Owens will showcase MetaCore at the EUROTOX Congress 2026 in Vienna, Austria.
Reported by DeepCyte
Presence & Recognition
DeepCyte will present at the Applied Pharmaceutical Analysis Conference highlighting DeeTox, its Single-Cell Mechanistic AI platform for cell-specific mechanism prediction.
Reported by DeepCyte